Rocket Pharmaceuticals Q1 net loss narrows on lower expenses

Rocket Pharmaceuticals

07/05/2026 21:09

Overview

US gene therapy developer's Q1 net loss narrowed yr/yr, reflecting lower R&D and G&A expenses

Company monetized Rare Pediatric Disease Priority Review Voucher for $180 mln, extending cash runway

Outlook

Company expects cash resources to fund operations into Q2 2028

Rocket anticipates providing a Danon disease program update in H2 2026

Result Drivers

LOWER OPERATING EXPENSES - Co said net loss narrowed mainly due to reduced R&D and G&A expenses, driven by lower manufacturing, development, and headcount costs, and absence of prior-year legal settlement

PRV MONETIZATION - Co sold Rare Pediatric Disease Priority Review Voucher for $180 mln, extending operational cash runway

Company press release: ID:nBw2kzm3Ca

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$47.6 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Rocket Pharmaceuticals Inc is $10.00, about 159.1% above its May 6 closing price of $3.86

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)